Levers for addressing medical underuse and overuse: achieving high-value health care

AG Elshaug, MB Rosenthal, JN Lavis, S Brownlee… - The Lancet, 2017 - thelancet.com
The preceding papers in this Series have outlined how underuse and overuse of health-care
services occur within a complex system of health-care production, with a multiplicity of …

How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries

S Vogler, V Paris, A Ferrario, VJ Wirtz… - … health economics and …, 2017 - Springer
This article discusses pharmaceutical pricing and reimbursement policies in European
countries with regard to their ability to ensure affordable access to medicines. A frequently …

Ongoing initiatives to improve the quality and efficiency of medicine use within the public healthcare system in South Africa; a preliminary study

JC Meyer, N Schellack, J Stokes, R Lancaster… - Frontiers in …, 2017 - frontiersin.org
Introduction: South Africa has an appreciable burden of both communicable and non-
communicable diseases as well as high maternal, neonatal, and child morbidity. In recent …

Barriers for access to new medicines: searching for the balance between rising costs and limited budgets

B Godman, A Bucsics, P Vella Bonanno… - Frontiers in Public …, 2018 - frontiersin.org
Introduction: There is continued unmet medical need for new medicines across countries
especially for cancer, immunological diseases, and orphan diseases. However, there are …

Evidence-based public policy making for medicines across countries: findings and implications for the future

B Godman, J Fadare, HY Kwon… - Journal of …, 2021 - becarispublishing.com
Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing
prevalence of non-communicable diseases (NCDs) and new premium priced medicines for …

The impacts of national centralized drug procurement policy on drug utilization and drug expenditures: the case of Shenzhen, China

L Chen, Y Yang, M Luo, B Hu, S Yin, Z Mao - International journal of …, 2020 - mdpi.com
In 2019, the Chinese government implemented the first round of the National Centralized
Drug Procurement (NCDP) pilot (so-called “4+ 7” policy) in mainland China, in which 25 …

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis

N Wang, Y Yang, L Xu, Z Mao, D Cui - BMC Public Health, 2021 - Springer
Abstract Background The Chinese government implemented the first round of National
Centralized Drug Procurement (NCDP) pilot (so-called “4+ 7” policy) in mainland China in …

[HTML][HTML] Leveraging the similarities between cost-effectiveness analysis and value-based healthcare

J Walraven, MS Jacobs, CA Uyl-de Groot - Value in Health, 2021 - Elsevier
Objectives This article aims to explore overlaps and differences between the emerging
concept of value-based healthcare (VBHC) and the established field of cost-effectiveness …

Essential medicines concept and health technology assessment approaches to prioritising medicines: selection versus incorporation

P Brhlikova, TA Deivanayagam, ZUD Babar… - … of Pharmaceutical Policy …, 2023 - Springer
Growing expenditure on medicines is impacting the sustainability of health systems [1]. The
global pharmaceutical market is estimated to grow at a rate of 3–6% annually through 2027 …

Sustainability in Health care by Allocating Resources Effectively (SHARE) 10: operationalising disinvestment in a conceptual framework for resource allocation

C Harris, S Green, AG Elshaug - BMC health services research, 2017 - Springer
Background This is the tenth in a series of papers reporting a program of Sustainability in
Health care by Allocating Resources Effectively (SHARE) in a local healthcare setting. After …